Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells
Ofrat Beyar‐Katz(Rambam Health Care Campus), Ron Ram(Tel Aviv University), Nino Kikozashvili(Tel Aviv University), Ronen Ben‐Ami(Tel Aviv University), David Shasha(Tel Aviv University), Yael Bar‐On(Tel Aviv University), Odelia Amit(Tel Aviv University), Chava Perry(Tel Aviv University), Irit Avivi(Tel Aviv Sourasky Medical Center), Ronit Gold(Tel Aviv University), Noam Benyamini(Tel Aviv University), Adrian Duek(Assuta Medical Center), Yair Herishanu(Tel Aviv University)
Cited by 41
Related Papers
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses
|mBio|2020|445
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164